ASPC 2020 Virtual Summit on CVD Prevention

 

ASPC 2020 Virtual Summit on CVD Prevention
Avatar

ASPC Expert Discussion on Biologics Usage for CV Risk Reduction, Efficacy of Polypharmacy, Statin Usage in Elderly, Ischemia Trial, BP Intensity Control, and Optimal Medical Therapy Approach

By ASPC 2020 Virtual Summit on CVD Prevention FEATURING Christie Ballantyne, Ann Marie Navar, David Maron, Keith Ferdinand, Paul Ridker
By ASPC 2020 Virtual Summit on CVD Prevention FEATURING Christie Ballantyne, Ann Marie Navar, David Maron, Keith Ferdinand, Paul Ridker
37 views
March 17, 2021
0 Comments
Login to view comments. Click here to Login

Featured Video

18:06
Lilly Obesity

Getting Patients Started with an Obesity Treatment Option for Adults

Feat. E. Lazarus

Featured Video

18:06
Lilly Obesity

Getting Patients Started with an Obesity Treatment Option for Adults

Feat. E. Lazarus
Videos
35:56
ASPC 2020 Virtual Summit on CVD Prevention

Integrating Imaging & Advanced Blood Testing for CVD Prevention/…

Feat. A. Agatston
08:09
ASPC 2020 Virtual Summit on CVD Prevention

Implementation of FIND FH Into Clinical Care at Penn Medicine: Can M…

Feat. S. Sheth
05:37
ASPC 2020 Virtual Summit on CVD Prevention

Lessons Learned from the ISCHEMIA Trial: How to Diagnose/Manage CAD …

Feat. D. Maron
11:29
ASPC 2020 Virtual Summit on CVD Prevention

Managing Patients With Stable CAD: When to Consider the Cath Lab? Wh…

Feat. D. Maron
21:16
ASPC 2020 Virtual Summit on CVD Prevention

ASPC Expert Discussion on Biologics Usage for CV Risk Reduction, Eff…

Feat. C. Ballantyne, A. Marie Navar, D. Maron, K. Ferdinand, P. Ridker
07:35
ASPC 2020 Virtual Summit on CVD Prevention

Continuity of Care for Patients With/At High Risk for CVD During COV…

Feat. A. Khera
08:31
ASPC 2020 Virtual Summit on CVD Prevention

Management of HF With Preserved Ejection Fraction: How Can We Preven…

Feat. D. Schocken
18:46
ASPC 2020 Virtual Summit on CVD Prevention

How Can We Prevent the Majority of CV Events? What Are the Milion He…

Feat. L. Sperling
19:17
ASPC 2020 Virtual Summit on CVD Prevention

NIH Scientific Approach to Inclusive Excellence: Why Diversity Matte…

Feat. H. A. Valantine
10:53
ASPC 2020 Virtual Summit on CVD Prevention

ASPC CVD Prevention Panel Discussion: How Can We Educate Our Patient…

Feat. L. Shaw, N. Wenger, V. Taqueti, R. Bullock-Palmer, E. Michos, M. Gulati, P. Taub
05:07
ASPC 2020 Virtual Summit on CVD Prevention

Expert Discussion on Transdermal Hormone Replacement Therapy & H…

Feat. L. Shaw, N. Wenger, V. Taqueti, R. Bullock-Palmer, E. Michos, M. Gulati, P. Taub
12:41
ASPC 2020 Virtual Summit on CVD Prevention

Disparities in the Use of Preventive Medications and Risk Factor Con…

Feat. K. Vu
27:57
ASPC 2020 Virtual Summit on CVD Prevention

100 Years from C-Reactive Protein to Anti-Inflammatory Therapy for A…

Feat. P. Ridker
28:45
ASPC 2020 Virtual Summit on CVD Prevention

Apolipoprotein B & CVD Risk: How Can We Improve CVD Prevention W…

Feat. A. Sniderman
32:07
ASPC 2020 Virtual Summit on CVD Prevention

Adverse Pregnancy Outcomes & CVD Risk: What Are the Risks and Ho…

Feat. R. Bullock-Palmer
07:13
ASPC 2020 Virtual Summit on CVD Prevention

FH Visual Aids in Patient Education Research Highlights: Can Distrib…

Feat. D. M. Harmon
05:51
ASPC 2020 Virtual Summit on CVD Prevention

HF With Preserved Ejection Fraction: How to Distinguish HFrEF & …

Feat. D. Schocken
15:01
ASPC 2020 Virtual Summit on CVD Prevention

Diagnosis/Management of CMD: How to Use Novel Imaging Tools to Under…

Feat. V. Taqueti
27:34
ASPC 2020 Virtual Summit on CVD Prevention

Atherosclerosis & MicroRNAs: How MicroRNAs Impacts Risk for Athe…

Feat. P. Toth
37:24
ASPC 2020 Virtual Summit on CVD Prevention

Primary Prevention by CAC vs. CTA: Which One Is Better and Why? - SC…

Feat. J. Min, K. Nasir
47:06
ASPC 2020 Virtual Summit on CVD Prevention

Jackson Heart Study Overview: Racial Disparity Trends, Risk Assessme…

Feat. H. Taylor
19:28
ASPC 2020 Virtual Summit on CVD Prevention

ASPC Panel Discussion on CV Risk Prevention With Nutrition, Hyperten…

Feat. K. Ferdinand, D. Maron, L. Sperling, I. Pina, H. Taylor
20:21
ASPC 2020 Virtual Summit on CVD Prevention

Discussion on CTA/CAC for Primary Prevention, Genetic Testing, LDL M…

Feat. R. Blankstein, S. Virani, A. Agatston, J. Min, S. Sheth, K. Nasir, A. Khera
28:23
ASPC 2020 Virtual Summit on CVD Prevention

New Insights Into Assessing Risk for Hispanic Patients: Why it Is Im…

Feat. I. Pina
16:33
ASPC 2020 Virtual Summit on CVD Prevention

Menopause and Its Impact on Women's CVD Health: How to Assess R…

Feat. E. Michos
14:00
ASPC 2020 Virtual Summit on CVD Prevention

Genetic Testing in Preventive Cardiology: Are Those With FH Mutation…

Feat. A. Khera
14:55
ASPC 2020 Virtual Summit on CVD Prevention

Statin Usage in Athletes: Is There Increased Muscle Injury With Stat…

Feat. P. D. Thompson
27:36
ASPC 2020 Virtual Summit on CVD Prevention

Sex Differences in Atherosclerosis: Is There a Sex Specific Phenotyp…

Feat. L. Shaw
16:05
ASPC 2020 Virtual Summit on CVD Prevention

Polypill for CVD Prevention: When Is Polypharmacy Appropriate? Can R…

Feat. K. Ferdinand
28:02
ASPC 2020 Virtual Summit on CVD Prevention

CVD Prevention for Women: What Are the Unique/Predominant Risk Facto…

Feat. N. Wenger